Willow Biosciences (TSE: WLLW – OTCQX: CANSF) CEO Trevor Peters joined Steve Darling from Proactive to share details the company has expanded their R&D capabilities to accommodate additional development programs. The company has added staff in both Vancouver, British Columbia and Mountain View, California to bring them to 55 employees including 42 of which are in technical roles.
Peters shares more about the scientists now working within the company and what programs they will be working on. Peters also shared some thoughts on their lead proprietary yeast strain which is now producing biosynthetic CBG at a commercial scale and is moving into revenue.